Guido Oelkers will leave Swedish Orphan Biovitrum (Sobi) by the end of January 2027 after overseeing a nine-year transformation that increased revenue more than fivefold and turned Sobi into a global rare disease group. The company said Oelkers is leaving to take another position, without identifying his next employer. Sobi’s board has started searching for a successor.Read More
